Quantcast
Last updated on April 17, 2014 at 12:35 EDT

Latest Abattis Bioceuticals Corp. Stories

2013-03-12 16:23:46

Sponsorship will fund completion of monograph to guide commercial production in Canada VANCOUVER, British Columbia, March 12, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp (OTC PINK: ATTBF) (CNSX: FLU) today announced that it has provided $10,000 sponsorship for the cannabis (cannabis sp.) monograph and therapeutic compendium currently under development by the American Herbal Pharmacopoeia (AHP). The monograph, scheduled for release in Spring 2013, will provide industry with a...

2013-03-11 16:25:20

VANCOUVER, March 11, 2013 /CNW/ - Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CNSX: FLU) (OTC: ATTBF), announces that it will not be proceeding with its $600,000 non-brokered private placement as previously announced in its Press Release dated February 12, 2013 as it is canvassing other avenues of financing through strategic relationships to prevent any dilution for its shareholders. About Abattis Bioceuticals Corp. Abattis Bioceuticals Corp. is a specialty...

2013-03-08 16:22:21

VANCOUVER, British Columbia, March 8, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CNSX: FLU) (OTC: ATTBF), is pleased to announce its participation in a research project led by Pamela Weathers, Professor of Biology and Biotechnology at Worcester Polytechnic Institute (WPI) in Worcester, Mass. that is investigating a whole plant therapeutic for treating malaria and other diseases, one that may also reduce drug resistance. Mr. Mike Withrow, Chief Executive...

2013-03-06 08:26:18

VANCOUVER, British Columbia, March 6, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has signed a letter of intent with Crudessence Kombucha Inc. ("RISE") to acquire the worldwide exclusive license "the License" to produce, distribute, market and sell a Kombucha tea infused or blended with additional nutraceutical and bioceutical formulas developed and owned by Abattis and its subsidiaries. Under the Terms of the...

2013-03-05 04:21:13

VANCOUVER, March 5, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has signed a Letter Of Intent for a multimillion dollar supply agreement with Cromogen Biotechnologies to purchase Cannabidiol or "CBD's" for the use of creating infused products to be sold in the US Natural Health Product Market(s).  Under the terms of the agreement the CBD's being supplied to Abattis are not listed as Scheduled 1 Drugs....

2013-03-04 08:27:49

VANCOUVER, March 4, 2013 /PRNewswire/ - Biocell Labs Inc., a wholly owned subsidiary of Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Dr. Paula Brown to provide the Company with the expertise and assistance needed to expand its capacity into the production of novel bio-pharmaceutical products. Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "we are very pleased to have Dr. Brown join the...

2013-02-04 04:21:23

VANCOUVER, Feb. 4, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of BCIT to study the growth rates and novel compounds present in baby spinach. Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to start on this project as it will substantiate the Vertical Automated Grow System (VAGS) acquired from Vertical Designs Ltd. and serve as a benchmark for growing,...

2013-01-24 12:25:55

VANCOUVER, British Columbia, Jan. 24, 2013 /PRNewswire/ -- CEO Mike Withrow of Abattis Bioceuticals Corp. www.abattis.com (OTCPINK: ATTBF) (CNSX: FLU), a specialty biotechnology company engaged in the licensing, marketing and formulation of unique and proprietary botanical, vitamin, and mineral products in several high growth natural health categories, has been interviewed on CEONews.Tv, a financial news network. The interview is available at: http://www.ceonews.tv/attbf/ In the interview...

2013-01-16 04:21:30

VANCOUVER, Jan. 16, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has been granted Intl Class 5 Trademark for DefenZall(TM) in Taiwan and the USA. Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to extend the intellectual property of the company as we grow our brands. This mark will be used to brand our proprietary Anti-Viral Nutraceutical Platform of products which...

2013-01-14 16:22:52

VANCOUVER, Jan. 14, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Andrew Riseman Ph.D. effective January 11, 2013. Dr. Riseman will be assisting the Company in Applied Biology and Plant Sciences. Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "We are pleased to have Dr. Riseman join our Abattis team. His expertise in tissue and plant breeding sciences will be a...